Figure 2.
The protein level of BDNF decreased by SD. (A–D) The GFAP-GFP transgenic mice were treated with sham (Control) or exposed to SD for 3 weeks, in the final week the mice were intraperitoneally injected with or without MCC950, fluoxetine, 5-HT2B receptors antagonist SB204741 (SB) or SB plus fluoxetine. The astrocytes sorted from GFAP-GFP mice were collected, representative blots for the expression of BDNF was shown in (A,C). Average BDNF level was quantified as the ratio between the BDNF and β-actin, n = 6 (the upper panels of B and D). Meanwhile, the BDNF level was also measured via ELISA, n = 6 (the lower panels of B and D). *p < 0.05, statistically significant difference compared with any other group (B); **p < 0.05, statistically significant difference compared with control and SD groups (B); *p < 0.05, statistically significant difference compared with any other group (D); **p < 0.05, statistically significant difference compared with fluoxetine group treated with sham (Control) and the other three groups treated with SD (D); #p < 0.05, statistically significant difference compared with any other group except for each other (D).